SSAs for pancreatic neuroendocrine tumours - ENETS 2020 Poster #1

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

SSAs for pancreatic neuroendocrine tumours – ENETS 2020 Poster #1

Dr Teresa Alonso Gordoa, Asst. Prof. Mauro Cives, Dr Faidon Laskaratos, Dr Elettra Merola, Dr Angela Lamarca, Dr Rachel van Leeuwaarde, Asst. Prof. Louis de Mestier, Dr Jorge Hernando, Dr Panpan Zhang

Dr Teresa Alonso Gordoa provides a summary of the poster presented at the ENETS 2020 conference: SSAs for pancreatic neuroendocrine tumours: is there any benefit when Ki-67 is ≥10%?

Dr Teresa Alonso Gordoa

Medical Oncologist

Hospital Universitario Ramón y Cajal

Spain

Asst. Prof. Mauro Cives

Medical Oncologist

University of Bari

Italy

Dr Faidon Laskaratos

Gastroenterologist

Royal Free Hospital

United Kingdom (UK)

Dr Elettra Merola

Gastroenterologist

Santa Chiara Hosptial

Italy

Dr Angela Lamarca

Medical Oncologist

The Christie NHS Foundation Trust

United Kingdom (UK)

Dr Rachel van Leeuwaarde

Endocrinologist

University Medical Centre Utrecht

Netherlands

Asst. Prof. Louis de Mestier

Gastroenterologist

Beaujon University Hosptial

France

Dr Jorge Hernando

Medical Oncologist

Vall d'Hebron University Hospital and Vall d'Hebron Institute of ...

Spain

Dr Panpan Zhang

Medical Oncologist

Peking University Cancer Hospital & Institute

China

Biography Disclosures

Dr Teresa Alonso Gordoa

Medical Oncologist

Hospital Universitario Ramón y Cajal

Spain

Dr Teresa Alonso Gordoa is a Medical Oncologist at the Medical Oncology Department of the Hospital Universitario Ramón y Cajal in Madrid. She finalized the degree of medicine by the University of Navarre in 2008 and the medical oncology specialization by the Hospital Universitario Clínico San Carlos in 2013. She is specialized in the care of patients with genitourinary, germ cell and endocrine tumors and in the early drug development unit. In addition, she is a member of the Spanish Society of Medical Oncology (SEOM), the European Society for Medical Oncology (ESMO), the Spanish Society of Genitourinary Oncology (SOGUG), the Germ Cell Group (GG) and the Spanish Group of Neuroendocrine Tumors (GETNE). She participates actively in research projects and clinical trials with international impact. She is a member of the honorary faculty of the University of Alcalá and a reviewer of indexed international journals. She has presented communications in national and international congresses and has participated in the publication of scientific articles in national and international journals.

Dr Teresa Alonso Gordoa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, Bayer, BMS, Eusa Pharma, Novartis, Roche, Sanofi Genzyme, Ipsen and Pfizer.

Biography Disclosures

Dr Angela Lamarca

Medical Oncologist

The Christie NHS Foundation Trust

United Kingdom (UK)

Dr Angela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumours (NETs)). She completed her training in Medical Oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs; during this period she received funding from ESMO (European Society for Medical Oncology) Translational Fellowship Programme, Pancreatic Cancer Research Fund and The Spanish Society of Medical Oncology (SEOM) Fellowship Grant Programme. Dr Lamarca has completed a Masters Degree in Molecular Biology of Cancer and a second Masters Degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2017 where she continues her Clinical and Translational Research career in HPB and NETs. She is actively involved in clinical trial design with special interest in NETs and HPB, focused on achieving a better understanding of these malignancies and identification of new therapies for improving patients’ outcome. Dr Angela Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group.

Dr Angela Lamarca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Bayer, EISAI, Merck, Mylan and Delcath, Novartis, Nutricia, Roche, SrtEx and QED.

Biography Disclosures

Dr Rachel van Leeuwaarde

Endocrinologist

University Medical Centre Utrecht

Netherlands

Dr Rachel van Leeuwaarde is an endocrinologist at the department of Endocrine Oncology at the University Medical Center of Utrecht, The Netherlands. She graduated cum laude from the Vrije University in Amsterdam and completed her Internal Medicine residency at the University Medical Center of Utrecht. During her endocrinology fellowship she developed an interest in endocrine oncology. Currently she is a staff member at the department of Endocrine Oncology at the University Medical Center of Utrecht and the Antoni van Leeuwenhoek hospital in Amsterdam. During her PhD trajectory on Multiple Endocrine Neoplasia Type 1, she completed a master in Epidemiology at the Julius Center for Health Sciences and Primary Care at the University Medical Center of Utrecht. Her PhD study was on “The impact of screening in Multiple Endocrine Neoplasia type 1”. Dr van Leeuwaarde’s research focusses on endocrine tumor syndromes such as Multiple Endocrine Neoplasia type 1 & 2 and Von Hippel Lindau disease with a special interest in screening and the health related quality of life in these syndromes.

Dr Rachel van Leeuwaarde has no relevant financial relationships to disclose.

Biography Disclosures

Asst. Prof. Louis de Mestier

Gastroenterologist

Beaujon University Hosptial

France

Dr Louis de Mestier serves as Assistant Professor in the Department of Pancreatology - Digestive Oncology at the ENETS Centre of Excellence of Beaujon University Hospital in Clichy (Université Paris-Cité), France. He obtained his specialist diplomas in Hepato-Gastroenterology and Digestive Oncology at the University of Reims, France. He has completed a PhD in Cancer Biology at the University of Paris-Cité in 2021. His clinical interests are on neuroendocrine tumors and pancreatic diseases. His main areas of clinical and translational research include tumor heterogeneity, molecular biomarkers and personalized treatment in NETs. He has been member of the Advisory Board of the French Neuroendocrine Tumor Networks (GTE, RENATEN) since 2020, and joined the Advisory Board of the European Neuroendocrine Tumor Society (ENETS) in 2022. He has participated in more than 100 medical publications, including more than 50 indexed papers in the field of NETs.

Asst. Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Novartis, Pfizer, Ipsen.

Biography Disclosures

Dr Jorge Hernando

Medical Oncologist

Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)

Spain

Dr Jorge Hernando is a Medical Oncologist at Vall d´Hebron University Hospital in Barelona, Spain. Jorge obtained his MD degree in 2010, and the Specialty in Medical Oncology in 2016 at the Miguel Servet University Hospital in Zaragoza, Spain. In 2017 he obtained his PhD and joined the Gastrointestinal and Endocrine Tumor Unit at Vall d´Hebron University Hospital. He is mainly committed to the clinical management of patients affected by gastrointestinal, neuroendocrine and endocrine malignancies. Jorge is involved in clinical and translational research projects at the Vall d´Hebron Institute of Oncology (VHIO) and he is also coordinator of the gastrointestinal and neuroendorine patient advocacy group. Dr Hernando is involved in professional societies including the American Society of Clinical Oncology (ASCO), European Society for Medical Onology (ESMO), European Neuroendocrine Tumor Society (ENETS) and Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE).

Dr Jorge Hernando has no relevant financial relationships to disclose.

Biography Disclosures

Dr Panpan Zhang

Medical Oncologist

Peking University Cancer Hospital & Institute

China

Dr Panpan Zhang works as a Medical Oncologist specialized in gastrointestinal carcinomas and neuroendocrine neoplasms (NENs) at the Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, in Beijing, China. She gained her MD degree in Medical Oncology and currently is a PhD student at the Peking University. Her major research interests are neuroendocrine tumors (NETs) and gastrointestinal carcinomas. From 2014, her clinical work and research has focused on the development of innovative treatments for NETs. She has just returned from a short-term fellowship at the Erasmus MC, The Netherlands. She is actively involved in several prospective clinical trials in NETs and gastrointestinal cancers, aimed at achieving a better understanding of these malignancies and improving clinical management of patients. In addition, she is a member of the multidisciplinary team at Beijing Cancer Hospital and the Chinese Neuroendocrine Tumor Society (CNETS).

Dr Panpan Zhang has no relevant financial relationships to disclose.

time | open 5 min | Mar 2020

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

DOWNLOAD THE POSTER

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

NET CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen and from Eisai Europe Limited.

Other programmes of interest

Prof. Dimitrios Tsakiris

Dr Lars Asmis

Podcast

27 min

Cancer and Thrombosis

Sep 2023

Dr Elisa Agostinetto

Prof. Valentina Guarneri

Interactive patient case

15 min

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Meta...

Sep 2023

Prof. Chee-Kiat Tan

Publication

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.